See more : Lara Exploration Ltd. (LRA.V) Income Statement Analysis – Financial Results
Complete financial analysis of Institute of Biomedical Research Corp. (MRES) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Institute of Biomedical Research Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Hyflux Ltd (HYFXF) Income Statement Analysis – Financial Results
- Gen 2 Technologies Inc. (MNIZ) Income Statement Analysis – Financial Results
- Openpay Group Ltd (OPY.AX) Income Statement Analysis – Financial Results
- LANXESS Aktiengesellschaft (LXS.SW) Income Statement Analysis – Financial Results
- Spielvereinigung Unterhaching Fußball GmbH & Co. KGaA (S6P.DE) Income Statement Analysis – Financial Results
Institute of Biomedical Research Corp. (MRES)
About Institute of Biomedical Research Corp.
Institute of Biomedical Research Corp. provides biomedical research and analytical services in Montenegro and internationally. Its services include regulatory control of industrial activities and products; scientific surveillance of the living environment; research and development of biomedical products and technologies; regulatory evaluation and certification of biomedical products; fundamental scientific research; and development of new diagnostic methods and experimental medical treatments. The company also researchers and develops new biomedical and food products; provides programs for graduate research studies in biomedical and environmental fields; offers two channel analog NMS, digital muscle stimulator, digital TENS, interferential, elite combination, portable four channel digital, portable ultra sound, and other healthcare devices; and provides photon red light for beauty, electric pain relief products, microcurrent electrical nerve stimulators, and high volt pulsed stimulators. In addition, it develops and commercializes microbicidal agents; disinfectant products; bandages for large burns, hard surface disinfection, microbicidal treatment of fabrics and textile products, insecticides against bed bugs and other textile goods, microbicidal towels, and mouthwash products; Purilair, an appliance that sterilizes compressed air circulating within medical instruments; colloidal silver and electro medical devices; and BioStim INF that is used for edema reduction, pain relief, and total treatment. Further, the company provides quality control, regulatory, healthcare, environmental services, environmental analysis, building decontamination, and environmental protection and management services; and regulatory certifications of new biomedical products. Institute of Biomedical Research Corp. was founded in 2010 and is based in Podgorica, Montenegro with a representative office in Montreal, Canada.
| Metric | 2010 | 2009 | 2008 | 2007 | 2006 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 1.25M | 786.11K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -1.25M | -786.11K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.34K | 20.66K | 147.78K | 0.00 | 92.90K | 0.00 | 0.00 |
| General & Administrative | 230.93K | 374.14K | 3.88M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 888.00 | 3.99K | 44.52K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 231.81K | 378.12K | 3.92M | 33.38K | 40.14K | 14.34K | 11.10K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 261.73K | 426.80K | 4.08M | 33.38K | 133.75K | 14.34K | 11.10K |
| Cost & Expenses | 261.73K | 426.80K | 5.33M | 819.48K | 133.75K | 14.34K | 11.10K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 11.68K | 16.49K | 35.65K | 0.00 | 5.12K | 6.04K | 4.00K |
| Depreciation & Amortization | 22.58K | 28.01K | 11.28K | -22.00 | 713.00 | -239.00 | -371.00 |
| EBITDA | -239.15K | -239.15K | -398.78K | -5.32M | -95.03K | -14.58K | -11.47K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -261.73K | -426.80K | -5.37M | -819.48K | -133.75K | -14.34K | -11.10K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -11.68K | -11.68K | 35.65K | 0.00 | -693.82K | -5.80K | -3.63K |
| Income Before Tax | -273.40K | -443.29K | -5.37M | -827.57K | 176.88K | -20.14K | -14.73K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 23.35K | 32.99K | 71.30K | -129.16K | 43.13K | 6.04K | 4.00K |
| Net Income | -273.40K | -443.29K | -5.37M | -690.30K | -176.88K | -20.14K | -14.73K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.05 | -0.09 | -1.88 | -0.39 | -0.13 | -0.02 | -0.01 |
| EPS Diluted | -0.05 | -0.09 | -1.88 | -0.39 | -0.13 | -0.02 | -0.01 |
| Weighted Avg Shares Out | 5.31M | 4.75M | 2.86M | 1.76M | 1.33M | 1.03M | 1.03M |
| Weighted Avg Shares Out (Dil) | 5.40M | 4.75M | 2.86M | 1.76M | 1.33M | 1.03M | 1.03M |
MRES: Dr. Esmarilda Dankaert Appointed Chief Innovation Officer (CINO) at M2Bio Sciences
MRES: M2Bio Food and Beverage Refocuses Strategy: Expanding Beyond CBD to Reach Global Consumers
RLAB: M2MMA Welcomes Legendary Muay Thai Icon Sagat Petchyindee to Advisory Board!
MRES: M2Bio Food and Beverage Wraps Up 2023/ 2024 Looking Ahead
MRES: M2Bio Sciences Provides Corporate Update
MRES: M2Bio Sciences Introduces M2BioKids: A Pioneering Approach to Elevating Childhood Health and Development
MRES: M2Enviro 2023 Year-End Review and 2024 Looking Forward
MRES: M2Biome 2023 Year-End Review and 2024 Looking Forward
Real American Announces Acquisition of M2MMA from MRES
Real American Announces Appointment of Officers and Directors
Source: https://incomestatements.info
Category: Stock Reports